LUX-Lung trials—not all mutations are created equal

被引：0
|
作者：
Lisa Hutchinson
机构：
来源：
Nature Reviews Clinical Oncology | 2015年 / 12卷 / 3期
关键词：
D O I：
10.1038/nrclinonc.2015.9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：127 / 127
相关论文
共 50 条
  • [1] TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
    Govindan, Ramaswamy
    Weber, Jason
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4419 - 4421
  • [2] ARE ALL RANDOMIZED TRIALS CREATED EQUAL
    TAYLOR, KM
    SKINNER, HA
    [J]. CONTROLLED CLINICAL TRIALS, 1988, 9 (03): : 243 - 243
  • [3] Not all CALR mutations are created equal
    He, Rong
    Hanson, Curtis A.
    Chen, Dong
    Oliveira, Jennifer L.
    Pardanani, Animesh
    Reichard, Kaaren K.
    Viswanatha, David S.
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2482 - 2483
  • [4] Are all KRAS mutations created equal?
    Stinchcombe, Thomas E.
    Der, Channing J.
    [J]. LANCET ONCOLOGY, 2011, 12 (08): : 717 - 718
  • [5] Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
    Wu, Yi-Long
    Sequist, Lecia V.
    Tan, Eng-Huat
    Geater, Sarayut L.
    Orlov, Sergey
    Zhang, Li
    Lee, Ki Hyeong
    Tsai, Chun-Ming
    Kato, Terufumi
    Barrios, Carlos H.
    Schuler, Martin
    Hirsh, Vera
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Boyer, Michael
    Mok, Tony
    Peil, Barbara
    Marten, Angela
    Yang, James Chih-Hsin
    Paz-Ares, Luis
    Park, Keunchil
    [J]. CLINICAL LUNG CANCER, 2018, 19 (04) : E465 - E479
  • [6] Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    Yang, James C-H
    Sequist, Lecia V.
    Geater, Sarayut Lucien
    Tsai, Chun-Ming
    Mok, Tony Shu Kam
    Schuler, Martin
    Yamamoto, Nobuyuki
    Yu, Chong-Jen
    Ou, Sai-Hong I.
    Zhou, Caicun
    Massey, Daniel
    Zazulina, Victoria
    Wu, Yi-Long
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : 830 - 838
  • [7] Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials
    Passaro, Antonio
    Gori, Bruno
    de Marinis, Filippo
    [J]. JOURNAL OF THORACIC DISEASE, 2013, 5 (04) : 383 - 384
  • [8] Inhibition of EGFR signaling:: All mutations are not created equal
    Gazdar, AF
    Minna, JD
    [J]. PLOS MEDICINE, 2005, 2 (11) : 1085 - 1087
  • [9] In colorectal cancer, not all KRAS mutations are created equal
    Rebecca Kirk
    [J]. Nature Reviews Clinical Oncology, 2011, 8 (1) : 1 - 1
  • [10] PARP inhibition - not all gene mutations are created equal
    Luo, Jun
    Antonarakis, Emmanuel S.
    [J]. NATURE REVIEWS UROLOGY, 2019, 16 (01) : 4 - 6
12345